Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment

Hoffmans, Ruth; Wagemakers, Alex; Drunen, Cornelis M. van; Hellings, Peter W.; Fokkens, Wytske J.

doi:10.1371/journal.pone.0192330

Cited by 47 publications

(15 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among all, 29% of the participants had AR criteria, 18% had ARS criteria, and 16% had CRS criteria. The authors investigated a number of risk factors, and emphasized that presence of AR, ARS and CRS symptoms constituted risk factors for each other, and that these three disorders had common and independent risk factors ( 305 ). Ha Yoo et al ( 306 ) studied the cost effectiveness of airway disease in Korea on 999 patients who admitted with respiratory complaints, and reported that AR and RS coexisted in 15.4% of the patients.…”

Section: Diagnosis Of Allergic Rhinitismentioning

confidence: 99%

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

Ecevit¹,

Özcan²,

Can³

et al. 2021

TAO

View full text Add to dashboard Cite

Object: To prepare a national guideline for Otorhinolaryngologist who treat allergic rhinitis patients. Methods: The study was conducted by three authors, namely the writing support team. The support team made the study plan, determined the writing instructions, chose the subgroups including the advisory committee, the advisors for authors and the authors. A workshop was organized at the very beginning to explain the details of the study to the team. Advisors took the chance to meet their coworkers in their subgroups and determined the main headings and subheadings of the guideline, together with the authors. After key words were determined by the authors, literature search was done in various databases. The authors keep in touch with the advisors and the advisors with the advisory committee and the support group at every stage of the study. National and International published articles as well as the abstracts of unpublished studies, imperatively presented in National Congresses, were included in this guideline. Only Guideline and meta-analyses published in last seven years (2013-2017) and randomized controlled studies published in last two years (2015-2017) were included. After all work was completed by the subgroups, support team brought all work together and edited the article. Results: A detailed guideline about all aspects of allergic rhinitis was created. Conclusion: The authors believe that this guideline will enable a compact and up-to-date information on allergic rhinitis to healthcare professionals. This guideline is the first in the field of Otolaryngology in Turkey. It should be updated at regular intervals.

show abstract

Section: Diagnosis Of Allergic Rhinitismentioning

confidence: 99%

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

Ecevit¹,

Özcan²,

Can³

et al. 2021

TAO

View full text Add to dashboard Cite

show abstract

“…Because of nasal symptoms (nasal itching, sneezing, rhinorrhoea, nasal congestion), ocular symptoms associated with allergic rhinoconjunctivitis (itching, tearing and redness of the eye) and other related symptoms (itching of the palate, postnasal drip, and cough), AR signi cantly impairs sleep quality and cognitive function, increases discomfort, irritability and fatigue and ultimately reduces quality of life (QoL) [3]. In addition, AR is heavily associated with comorbidities such as asthma [4,5] and rhinosinusitis [6]. As a result, AR causes substantial direct and indirect costs associated with medical expenses and reduction in work and school performance, respectively [3].…”

Section: Background Rationalementioning

confidence: 99%

Efficacy of Mhealth Interventions to Improve Nasal Corticosteroid Adherence in Allergic Rhinitis: A Systematic Review Protocol

Baxter

Schwarze

Bush

et al. 2021

Preprint

View full text Add to dashboard Cite

IntroductionMobile health (mHealth) is a potential tool to improve nasal corticosteroid (NCS) adherence in allergic rhinitis (AR), which remains largely poor and inconsistent for many. We plan to undertake a systematic review to synthesise the evidence on the efficacy of mHealth interventions to improve NCS adherence in AR. Methods and analysisA systematic search will be conducted in the electronic databases MEDLINE, EMBASE and CENTRAL (Cochrane Central Register of Controlled Trials), filtered for publication dates between January 2010 and August 2020. The search is scheduled to commence in August 2020. We will scan reference lists of included studies for additional eligible papers. Relevant unpublished or in-progress trials will be searched for through trial registries. Randomised controlled trials that examine the efficacy of mHealth interventions to improve NCS adherence in AR are to be included. Two reviewers will independently screen and extract relevant data from the included studies and perform a risk-of-bias assessment using the Cochrane risk of bias tool 2.0. We will perform a narrative synthesis with relevant data tables and, if deemed clinically relevant and statistically adequate, meta-analyses using random-effects modelling. The Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) statement will be used to help guide the reporting of this review. Ethics and disseminationSince this systematic review will be exclusively based on published and retrievable literature, no ethics approval will be sought. The findings of this systematic review will be disseminated at appropriate conferences/webinars while being published in an open access peer-reviewed journal.Registration: In accordance with the guidelines, our systematic review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 27th August 2020. PROSPERO registration number CRD42020198879.

show abstract

“…Згідно з сучасними уявленнями, вперше представленими в EPOS 2007 і уточнених в EPOS 2020, визначення гострий риносинусит (ГРС) включає: вірусний, післявірусний і бактеріальний риносинусит [1]. Відомо, що дорослі переносять від двох до п'яти епізодів гострого вірусного риносинуситу (ГВРС, або застуди) на рік, а школярі можуть -від 7 до 10 епізодів застуди на рік [1,2]. Поширеність гострого післявірусного риносинуситу (ГПВРС) складає 18 % (17-21 %) [3].…”

Section: клініко-мікробіологічні паралелі відкладеного призначення антибіотиків у пацієнтів з гострим риносинуситомunclassified

Clinical and microbiological parallels of delayed prescribing of antibiotics in patients with acute rhinosinusitis

Hariri

Koshel

Попович

2020

OTORHINOLARYNGOLOGY

View full text Add to dashboard Cite

Topicality: The rate of acute bacterial rhinosinusitisis 0,5-2% of all cases of acute rhinosinusitis, however, up to 60 % of patients receive the course of antibiotics since the first day of disease. It is well known that earlier use of antibiotics has almost no effect on the development of bacterial ARS and its complications. The purpose of study was to examine the bacterial spectrum of post-viral RS and evaluate clinical and bac-teriological efficiency of polyvalent bacteriophage in technique of delayed prescribing of antibiotics in comparison with the patients receiving standard APVRS therapy. Material and methods: 155 adult patients with acute post-viral RS participated in the trial who were given either standard therapy or polyvalent bacteriophage in addition to the standard therapy. In conjunction with the treatment, the microbiological composition of nasal microflora was examined and its comparison with clinical dynamics was undertaken. Evaluation criteria: decrease in intensity of disease symptoms evaluated in accordance with MSS scale system during each visit in comparison with the 1st visit, antibiotic prescribing frequency, dynamics of microbiological changes. Outcomes and discussion: The use of polyvalent bacteriophagein addition to the standard therapy of acute post-viral rhinosinusitis as a part of technique of delayed prescribing of antibioticsensures clinically significant decrease in the intensity of rhinorrhea symptoms, nasal congestion and post-nasal drip on the third day of supervision (p<0.05). It reduces the prescription of antibacterial medicines by 20%without negative impact on overall treatment results. Decrease in the number of prescription of antibacterial therapy correlates with the fair reduction in bacterial loadwith Staphylococcus aureus and typical representative of ABRS – S. pneumoniae, Haemophilus influenza and M. catarrhalis. Therefore, the intervention group in comparison with the control group has had “therapeutic advantage” during the first days of treatment which allowed to assess the course of disease as a “positive” and avoid in appropriate use of antibiotics. There have been documented no patients with adverse effects during the course of treatment. Conclusion: polyvalent bacteriophage is a safe and effective medication for additional treatment of acute post-viral rhinosinusitis intended to reduce the use of antibiotics. The inclusion of the medication into the treatment regimen could be recommended to the patients as a part of technique of delayed prescribing of antibiotics.

show abstract

Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment

Cited by 47 publications

References 53 publications

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

Efficacy of Mhealth Interventions to Improve Nasal Corticosteroid Adherence in Allergic Rhinitis: A Systematic Review Protocol

Clinical and microbiological parallels of delayed prescribing of antibiotics in patients with acute rhinosinusitis

Contact Info

Product

Resources

About